The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening
Official Title: Parallel Controlled Study of Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening in the High-risk Population
Study ID: NCT05447169
Brief Summary: The investigators intend to compare Epstein-Barr virus antibody and Epstein-Barr virus DNA screening efficacy in first-degree relatives of nasopharyngeal carcinoma patients.
Detailed Description: The investigators intend to test Epstein-Barr virus antibodies (Viral Capsid Antigen-immunoglobulin A, Epstein-Barr nuclear antigen 1-immunoglobulin A, early antigen-immunoglobulin A, Zta-immunoglobulin A, Rta-immunoglobulin G, Bnlf 2b) by ELISA and Epstein-Barr virus DNA by quantitative polymerase chain reaction, target sequencing and CRISPR-associated protein 12a in nasopharyngeal brushing and plasma of the same population at high-risk of nasopharyngeal carcinoma so as to determine the best method in nasopharyngeal carcinoma screening.
Minimum Age: 30 Years
Eligible Ages: ADULT
Sex: MALE
Healthy Volunteers: No
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Name: Ming-Yuan Chen, MD, PhD
Affiliation: Sun Yat-sen University
Role: STUDY_CHAIR